(lp0
S'Earnings Reaction History: TrovaGene, Inc., 75.0% Follow-Through Indicator, 7 ... Nasdaq - 14 hours ago TrovaGene, Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement.'
p1
aS'Trovagene nabs rights to leukemia candidate from Nerviano Medical Seeking Alpha - 13 hours ago Trovagene  inks a license agreement with Italian drug discovery firm Nerviano Medical Sciences, S.r.l. for exclusive global development and commercialization rights to NMS-1286937, renamed PCM-075, for the potential treatment of acute&nbsp;...Trovagene , Nerviano Announce License Agreement for PCM-075 - StreetInsider.com'
p2
aS'Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and ... PR Newswire  - Mar 1, 2017 SAN DIEGO, March 1, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will report financial results for the fourth quarter and year ended December 31, 2016&nbsp;...'
p3
aS'Trovagene Announces Broadening Network of Commercial Distributors PR Newswire  - Jan 12, 2017 SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  technologies, today announced that it has signed agreements with seven strategic partners across Europe and the Middle East for&nbsp;...Trovagene inks seven deals for commercialization of liquid biopsy tests ex-US - Seeking Alpha'
p4
aS'Trovagene and Boreal Genomics Announce Strategic Partnership PR Newswire  - Nov 30, 2016 SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, today announced it has entered into a long-term Supply and Distribution Agreement with Boreal Genomics,&nbsp;...'
p5
aS'Trovagene announces a reorganization to accelerate global distribution of ... PR Newswire  - Dec 13, 2016 SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will increase its focus on the global distribution of kits and systems to clinical&nbsp;...Trovagene to Focus More on Liquid Biopsy Testing Market - Yahoo Finance'
p6
aS'Trovagene to Attend the 29th Annual ROTH Conference PR Newswire  - Feb 28, 2017 SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March 12-15, 2017, at the Ritz Carlton Laguna&nbsp;...'
p7
aS"Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments PR Newswire  - Nov 9, 2016 SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, today reported its financial results and accomplishments for the third quarter ended September 30, 2016.TrovaGene's  CEO Bill Welch on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha"
p8
aS"Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands ... PR Newswire  - Feb 1, 2016 SAN DIEGO, Feb. 1, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc.  establishing health benefit access to&nbsp;...Could This Be the Turning Point for TrovaGene? - 24/7 Wall St.Here's Why TrovaGene  Stock is Soaring Today - TheStreet.com"
p9
aS'Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen ... PR Newswire  - Mar 28, 2016 SAN DIEGO, March 28, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of cell-free molecular diagnostics, announced today that its Board of Directors terminated the employment of CEO Antonius Schuh and CFO Stephen Zaniboni for&nbsp;...Trovagene removes CEO, CFO for cause and files complaint - Seeking AlphaBiotech Trovagene Tumbles After Firing, Suing Its Top Executives - Bloomberg'
p10
a.